Dynegy share#snapshot#suffix

Dynegy für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1J5JU / ISIN: US26817R1086

10.01.2025 12:58:58

Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1

(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).

Myotonic dystrophy type 1 is a genetic disease that causes progressive muscle weakness and loss.

The company said results from the study showed that DYNE-101 continued to demonstrate a compelling impact on key disease biomarkers.

Dyne plans to initiate a Registrational Expansion Cohort in ACHIEVE, with submission for accelerated approval expected in the first half of 2026.

news about Dynegy Incto the shares news

no news available.

analysis to Dynegy Incto the shares analysis

portfolio#add_instrument#headline
portfolio#add_instrument#ad
portfolio#add_instrument#error